S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
S&P 500   4,455.48
DOW   34,798.00
QQQ   373.33
pixel
NASDAQ:ARGX

argenx Stock Forecast, Price & News

$308.00
-10.01 (-3.15 %)
(As of 09/24/2021 04:00 PM ET)
Add
Compare
Today's Range
$306.73
$314.00
50-Day Range
$295.85
$350.58
52-Week Range
$238.58
$382.15
Volume102,606 shs
Average Volume179,162 shs
Market Capitalization$15.84 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.92
30 days | 90 days | 365 days | Advanced Chart
Receive ARGX News and Ratings via Email

Sign-up to receive the latest news and ratings for argenx and its competitors with MarketBeat's FREE daily newsletter.


argenx logo

About argenx

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Breda, the Netherlands.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.70 out of 5 stars

Medical Sector

878th out of 1,351 stocks

Biological Products, Except Diagnostic Industry

134th out of 193 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











argenx (NASDAQ:ARGX) Frequently Asked Questions

Is argenx a buy right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for argenx in the last twelve months. There are currently 7 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" argenx stock.
View analyst ratings for argenx
or view top-rated stocks.

What stocks does MarketBeat like better than argenx?

Wall Street analysts have given argenx a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but argenx wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is argenx's next earnings date?

argenx is scheduled to release its next quarterly earnings announcement on Thursday, October 28th 2021.
View our earnings forecast for argenx
.

How were argenx's earnings last quarter?

argenx SE (NASDAQ:ARGX) issued its earnings results on Thursday, July, 29th. The company reported $1.98 earnings per share for the quarter, topping analysts' consensus estimates of ($3.38) by $5.36. The business earned $320.06 million during the quarter, compared to analyst estimates of $44.46 million. argenx had a negative net margin of 63.22% and a negative trailing twelve-month return on equity of 21.19%.
View argenx's earnings history
.

How has argenx's stock price been impacted by COVID-19?

argenx's stock was trading at $133.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ARGX stock has increased by 130.2% and is now trading at $308.00.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for ARGX?

16 equities research analysts have issued 1-year price targets for argenx's stock. Their forecasts range from $250.00 to $430.00. On average, they anticipate argenx's stock price to reach $340.62 in the next year. This suggests a possible upside of 10.6% from the stock's current price.
View analysts' price targets for argenx
or view top-rated stocks among Wall Street analysts.

Who are argenx's key executives?

argenx's management team includes the following people:
  • Tim van Hauwermeiren, Chief Executive Officer & Executive Director
  • R. Keith Woods, Chief Operating Officer
  • Karl Gubitz, Chief Financial Officer
  • Hans J. W. de Haard, Chief Scientific Officer
  • Wim Parys, Chief Medical Officer

What other stocks do shareholders of argenx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other argenx investors own include Galapagos (GLPG), Kohl's (KSS), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), Pfizer (PFE), CRISPR Therapeutics (CRSP), Fate Therapeutics (FATE), NVIDIA (NVDA) and Sarepta Therapeutics (SRPT).

When did argenx IPO?

(ARGX) raised $65 million in an initial public offering (IPO) on Thursday, May 18th 2017. The company issued 3,600,000 shares at $18.18 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is argenx's stock symbol?

argenx trades on the NASDAQ under the ticker symbol "ARGX."

Who are argenx's major shareholders?

argenx's stock is owned by many different retail and institutional investors. Top institutional investors include Price T Rowe Associates Inc. MD (10.86%), FMR LLC (9.06%), Artisan Partners Limited Partnership (5.74%), Bellevue Group AG (1.89%), Avoro Capital Advisors LLC (1.84%) and Redmile Group LLC (1.54%).

Which institutional investors are selling argenx stock?

ARGX stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Price T Rowe Associates Inc. MD, Redmile Group LLC, Ikarian Capital LLC, Federated Hermes Inc., TimesSquare Capital Management LLC, ArrowMark Colorado Holdings LLC, and SG3 Management LLC.

Which institutional investors are buying argenx stock?

ARGX stock was acquired by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., BlackRock Inc., Artisan Partners Limited Partnership, Clearbridge Investments LLC, Public Sector Pension Investment Board, Bamco Inc. NY, and Woodline Partners LP.

How do I buy shares of argenx?

Shares of ARGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is argenx's stock price today?

One share of ARGX stock can currently be purchased for approximately $308.00.

How much money does argenx make?

argenx has a market capitalization of $15.84 billion and generates $41.60 million in revenue each year. The company earns $-604,190,000.00 in net income (profit) each year or ($13.30) on an earnings per share basis.

How many employees does argenx have?

argenx employs 336 workers across the globe.

What is argenx's official website?

The official website for argenx is www.argenx.com.

Where are argenx's headquarters?

argenx is headquartered at Willemstraat 5, Breda P7, 4811 AH.

How can I contact argenx?

argenx's mailing address is Willemstraat 5, Breda P7, 4811 AH. The company can be reached via phone at (176) 303-0488 or via email at [email protected].


This page was last updated on 9/26/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.